Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day

WASHINGTON, Feb. 1, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) VNDA, a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs, today announced that members of its management team will participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day on Tuesday, February 2, 2016 in New York City.

For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Investor Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-to-participate-in-the-canaccord-genuity-rare-disease-biopharma-one-on-one-day-300213055.html

SOURCE Vanda Pharmaceuticals Inc.